| abstract |
The present disclosure provides methods of using a gateway kinase 1 (Chk1) inhibitor in the treatment of cancer in a subject having at least a moderate tumor mutational burden (TMB) or a genetic abnormality in one or more specific genes associated with replication stress. Accordingly, provided are methods of treating cancer in a subject with at least an intermediate tumor mutational burden (TMB-I). Also provided are methods of treating cancer in a subject having a genetic abnormality in one or more specific genes selected from cell cycle regulatory genes, replication stress genes, oncogenic mutations, and DNA damage response and repair network genes. Methods of selecting a subject for Chk1 inhibition therapy are provided. The methods may comprise administering to the subject an effective amount of a SRA737 compound, in some instances in combination with a low dose gemcitabine. |